Fig. 2From: Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumourPatient-based scatter plots of the cumulative tumour-absorbed dose (TAD) against the diameter change of the target lesion (%). A Cumulative TADmax, B Cumulative TADpeak, and C Cumulative TAD41Back to article page